Guggenheim raised the firm’s price target on InflaRx (IFRX) to $22 from $10 and keeps a Buy rating on the shares after the company announced topline data from a Phase 2a basket study exploring INF904 in hidradenitis suppurativa and chronic spontaneous urticaria. The firm raised its view of the odds of success in HS to 65% from 30% following the data and models peak HS sales of about $1.5B.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx reports Phase 2a data for INF904 in HS, CSU
- InflaRx Announces Positive Phase 2a Results for INF904 in HS and CSU
- InflaRx Reports Q3 2025 Financial Results Highlighting Operational Challenges
- Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
- Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab